Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
The decrease in O 2 concentrations and the increase in H 2 O 2 concentrations in our study showed that S
The natural compound apocynin (Apo) has mitigating properties that are involved in inflammatory responses (Cheng et al., 2017), with preclinical PD models showing that it could prevent MPTP-induced nigral cell loss, indicating its potential use for mitochondrial dysfunction in PD (Ghosh et al., 2017)
10.2174/1568011054222364 7 BazhabayiM.QiuX.LiX.YangA.WenW.ZhangX.et al (2021)
Glycolic Acid Serum : Glycolic Acid is a renowned exfoliating agent that effectively sloughs away dead skin cells, unclogs pores, and promotes cell turnover, revealing fresher, more youthful-looking skin underneath
Disclosures: Athanasios Angelakis: Nothing to Disclose, Pietro Lampertico: ROCHE PHARMA/DIAGNOSTICS, GILEAD SCIENCES, GSK, ABBVIE, JANS: Advisor, Vana Sypsa: Nothing to Disclose, George Dalekos: Nothing to Disclose, Cihan Yurdaydin: Nothing to Disclose, Thomas Berg: Nothing to Disclose, IOANNIS GOULIS: Nothing to Disclose, Jose Luis Calleja: Nothing to Disclose, Harry Janssen: Gilead Sciences: and consultant, Gilead Sciences: Grant/Research Support, GlaxoSmithKline: Grant/Research Support, Janssen: Grant/Research Support, Roche: Grant/Research Support, Vir Biotechnology Inc.: Grant/Research Support, Aligos: Consultant, Gilead Sciences: Consultant, GlaxoSmithKline: Consultant, Grifols: Consultant, Roche: Consultant, Vir Biotechnology Inc: Consultant, Precision Biosciences: Consultant, Maria Buti: Nothing to Disclose, Nothing to Disclose, George Papatheodoridis: Abbvie: Advisor, Abbvie: Speaking and Teaching, Abbvie: Grant/Research Support, Astra Zeneca: Advisor, Astra Zeneca: Speaking and Teaching, Abbvie: Advisor, Abbvie: Speaking and Teaching, Astra Zeneca: Advisor, Astra Zeneca: Speaking and Teaching, Genesis: Advisor, Genesis: Speaking and Teaching, Gilead: Advisor, Gilead: Speaking and Teaching, Gilead: Grant/Research Support, GlaxoSmithKline: Advisor, Ipsen: Advisor, Ipsen: Speaking and Teaching, Novo Nordisk: Advisor, Novo Nordisk: Speaking and Teaching, Roche: Advisor, Roche: Speaking and Teaching, Takeda: Advisor 367 IMMUNE-RELATED ADVERSE EVENTS WITH LOW-DOSE NIVOLUMAB IN PATIENTS WITH CHRONIC HEPATITIS B: EXPERIENCE FROM 3 CLINICAL STUDIES Edward Gane 1 Tawesak Tanwandee 2 Bitna Yi 3 Teri Chew 3 Irina Botros 3 Danielle Shing 4 Heba Abdullah 3 Leonard Sowah 3 Frida Abramov 3 Ben Da 3 Audrey Lau 3 Anu Osinusi 3 Tak Yin Owen Tsang 5 Anchalee Avihingsanon 6 , 1 University of Auckland, Auckland, New Zealand, 2 Faculty of Medicine Siriraj Hospital, Bangkok, Thailand, 3 Gilead Sciences, Inc., Foster City, CA, USA, 4 Gilead Sciences, Inc., Cambridge, UK, 5 Infectious Disease Centre, Princess Margaret Hospital, Kwai Chung, Hong Kong, 6 HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand Background: Anti programmed death-1/programmed death ligand-1 (PD-1/PD-L1) monoclonal antibodies (mAbs) are being investigated at low doses for finite treatment of chronic hepatitis B (CHB) virus infection
